Managing IP is part of the Delinian Group, Delinian Limited, 8 Bouverie Street, London, EC4Y 8AX, Registered in England & Wales, Company number 00954730
Copyright © Delinian Limited and its affiliated companies 2023

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement
Cookies Settings

COVID-19 puts spotlight on compulsory licensing jitters

Charlotte Kilpatrick
April 09, 2020
Share
crown-use.jpg

Some pharma innovators say there is no reason to fear compulsory licensing but others are nervous about the precedent the pandemic will set

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Take a Free Trial or Login

Tags

IP StrategyNewsEuropean UnionPatentsEuropeJurisdictionsJurisdictions
kilpatrick-charlotte-300px.png
Charlotte Kilpatrick
Reporter Managing IP
Contact
Charlotte reports on patent-related issues. She often covers the European market, focusing on developments including FRAND, licensing and trade secrets. She is particularly interested in how new technologies affect IP challenges in the pharmaceutical industry.
more from across site and ros bottom lb

More from across our site

Digital India.jpg
What IP counsel want from India’s digital law overhaul
IP counsel urge the government to restrict safe harbour exceptions available to intermediaries and clear up doubts with the existing law
Sukanya Sarkar, May 31, 2023
Chatgpt.jpg
Weekly take: Fake judgment row shouldn’t spark AI concern
A New York lawyer could face sanctions after citing fake judgments generated by ChatGPT, but that doesn’t mean practitioners should shy away from AI
Sukanya Sarkar, May 31, 2023
KerstinJorna.jpg
Breaking: UPC chief urges EU to rethink SEP plan
Klaus Grabinski told delegates at a UPC inauguration event that the proposed SEP regulation would limit access to justice
Rory O’Neill, May 30, 2023
EPO
This week on MIP: France v EPO spat, Med-El loss
We provide a rundown of Managing IP’s news and analysis coverage from the week, and review what’s been happening elsewhere in IP
Rory O’Neill, May 26, 2023
INTA 2023.jpeg
AI, thriftiness, and law firm culture: takeaways from INTA 2023
Sukanya Sarkar shares her thoughts on this year’s annual meeting in Singapore, where debates ranged from AI opportunities to improving law firm culture
Sukanya Sarkar, May 26, 2023
dollar money and judges gavel on table
Counsel: Federal Circuit right to clarify attorney fee challenge
The court’s ruling is a good reminder that US parties aren’t guaranteed attorney fees just because they win, say sources
Rani Mehta, May 25, 2023
economic crash-comp.jpg
Three principles for managing trademarks during a downturn
With business confidence in a shaky state, Rachel Tan and Lisa Yong of Rouse discuss how in-house IP teams can manage their trademark portfolios through uncertain times
Lisa Yong, May 25, 2023
Entrance to the Royal Court of Justice
Med-El loses UK appeal in Advanced Bionics fight
The Court of Appeal had stern words for Med-El’s representatives after they highlighted a deputy judge’s background as a solicitor
Rory O’Neill, May 24, 2023
Credit: Dennis / Adobe Stock
Three takeaways from Intel’s PTAB win
Funders and NPEs say asserting patent portfolios can minimise risk at the USPTO’s PTAB, where procedure remains a controversial topic
Rani Mehta, May 24, 2023
Berlin / Germany - September 22, 2019: Sanofi Germany - Berlin b
Amgen v Sanofi won’t upend in-house IP strategies: counsel
The US Supreme Court’s ruling wasn’t a surprise and reflects a trend that had already been bubbling away for a while, say tech and pharma counsel
Rani Mehta, May 23, 2023